We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Hemoglobin Assay Based on Fluorescent Quenching Technology

By HospiMedica staff writers
Posted on 23 Nov 2006
A new assay for glycated hemoglobin (A1C) is based on fluorescent quenching technology. More...
The amount of glucose that combines with the hemoglobin is directly proportional to the total amount of glucose that is currently in an individual's system. The assay will aid in the diagnosis of diabetes and subsequent follow-up of patients.

The A1C level provides an overall record of glucose levels for as long as the individual red blood cells live, which is about two or three months. Whereas the fasting glucose test gives an indication of current glucose levels, the A1C gives a picture of average levels over the whole two-to-three-month period.

The fluorescence of a conjugate of boronic acid and a fluorophore is reduced (or "quenched”) upon binding to cis-diol groups that are present on carbohydrates attached to hemoglobin molecules. Utilizing solid state opto-electronic technology, a desktop reader quantifies the concentration of A1C in the sample. The total amount of hemoglobin is then quantified by absorption measurement. The combination of these two values produces an A1C % result.

Called Quo-Test, the fully automated homogenous assay system was developed by Quotient Diagnostics (Surrey, UK). There are no separation steps, and the system controls all the critical steps that may influence or affect the quality of the result. Results are delivered in about three minutes from a blood sample of less than 5 µl. The starter kit contains a reader, barcode scanner, mini-printer, and a pack of 10 disposable cartridges.

Diabetes is one of the most challenging health problems in the 21st century, with close to 200 million people worldwide already diagnosed as having the disease. In addition, there is strong reason to believe that more than half of the diabetics in the world remain undiagnosed. According to Quotient's CEO David Chatterton, the trend is for both diagnosis and follow-up to be performed in special clinics, hence the development of Quo-Test. "We have drawn on our broad experience in both assay and instrument development to create an instrument that we are confident will have a major impact on diabetes care,” he explained.




Related Links:
Quotient Diagnostics

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Enteral Feeding Pump
SENTINELplus
Exam Table
PF400
Gold Member
Electrode Solution and Skin Prep
Signaspray
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.